Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
377 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H2 2016', provides an overview of the Pulmonary Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis - The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects - The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Pulmonary Fibrosis Overview 7 Therapeutics Development 8 Pulmonary Fibrosis - Therapeutics under Development by Companies 10 Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 16 Pulmonary Fibrosis - Pipeline Products Glance 17 Pulmonary Fibrosis - Products under Development by Companies 20 Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 28 Pulmonary Fibrosis - Companies Involved in Therapeutics Development 29 Pulmonary Fibrosis - Therapeutics Assessment 103 Drug Profiles 118 Pulmonary Fibrosis - Dormant Projects 345 Pulmonary Fibrosis - Discontinued Products 352 Pulmonary Fibrosis - Product Development Milestones 353 Appendix 361
List of Tables
Number of Products under Development for Pulmonary Fibrosis, H2 2016 23 Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2016 24 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Development by Companies, H2 2016 (Contd..4) 29 Number of Products under Development by Companies, H2 2016 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Development, H2 2016 34 Products under Development by Companies, H2 2016 35 Products under Development by Companies, H2 2016 (Contd..1) 36 Products under Development by Companies, H2 2016 (Contd..2) 37 Products under Development by Companies, H2 2016 (Contd..3) 38 Products under Development by Companies, H2 2016 (Contd..4) 39 Products under Development by Companies, H2 2016 (Contd..5) 40 Products under Development by Companies, H2 2016 (Contd..6) 41 Products under Development by Companies, H2 2016 (Contd..7) 42 Products under Investigation by Universities/Institutes, H2 2016 43 Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2016 44 Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016 45 Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 46 Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 47 Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 48 Pulmonary Fibrosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 49 Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 50 Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016 51 Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2016 52 Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2016 53 Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 54 Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 55 Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2016 56 Pulmonary Fibrosis - Pipeline by Chrysalis Pharma SAS, H2 2016 57 Pulmonary Fibrosis - Pipeline by Clanotech AB, H2 2016 58 Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2016 59 Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2016 60 Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 61 Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016 62 Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H2 2016 63 Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64 Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2016 65 Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2016 66 Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2016 67 Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 68 Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2016 69 Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2016 70 Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2016 71 Pulmonary Fibrosis - Pipeline by GNI Group Ltd., H2 2016 72 Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 73 Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2016 74 Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H2 2016 75 Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2016 76 Pulmonary Fibrosis - Pipeline by Immunomet Therapeutics, Inc. , H2 2016 77 Pulmonary Fibrosis - Pipeline by Inventiva, H2 2016 78 Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 79 Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2016 80 Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2016 81 Pulmonary Fibrosis - Pipeline by KineMed, Inc., H2 2016 82 Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 83 Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 84 Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2016 85 Pulmonary Fibrosis - Pipeline by Lung Therapeutics, Inc, H2 2016 86 Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2016 87 Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2016 88 Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2016 89 Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2016 90 Pulmonary Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016 91 Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2016 92 Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2016 93 Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 94 Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H2 2016 95 Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2016 96 Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2016 97 Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 98 Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2016 99 Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H2 2016 100 Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2016 101 Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 102 Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2016 103 Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H2 2016 104 Pulmonary Fibrosis - Pipeline by Sanofi, H2 2016 105 Pulmonary Fibrosis - Pipeline by Sirnaomics, Inc., H2 2016 106 Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics, Inc., H2 2016 107 Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2016 108 Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016 109 Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 110 Pulmonary Fibrosis - Pipeline by Terpenoid Therapeutics, Inc., H2 2016 111 Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 112 Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2016 113 Pulmonary Fibrosis - Pipeline by Vault Pharma Inc., H2 2016 114 Pulmonary Fibrosis - Pipeline by Vericel Corporation, H2 2016 115 Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2016 116 Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2016 117 Assessment by Monotherapy Products, H2 2016 118 Number of Products by Stage and Target, H2 2016 120 Number of Products by Stage and Mechanism of Action, H2 2016 125 Number of Products by Stage and Route of Administration, H2 2016 130 Number of Products by Stage and Molecule Type, H2 2016 132 Pulmonary Fibrosis - Dormant Projects, H2 2016 360 Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2016 361 Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2016 362 Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2016 363 Pulmonary Fibrosis - Dormant Projects (Contd..4), H2 2016 364 Pulmonary Fibrosis - Dormant Projects (Contd..5), H2 2016 365 Pulmonary Fibrosis - Dormant Projects (Contd..6), H2 2016 366 Pulmonary Fibrosis - Discontinued Products, H2 2016 367
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
